You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

TRI-NORINYL 21-DAY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tri-norinyl 21-day patents expire, and when can generic versions of Tri-norinyl 21-day launch?

Tri-norinyl 21-day is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.

The generic ingredient in TRI-NORINYL 21-DAY is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRI-NORINYL 21-DAY?
  • What are the global sales for TRI-NORINYL 21-DAY?
  • What is Average Wholesale Price for TRI-NORINYL 21-DAY?
Summary for TRI-NORINYL 21-DAY
Drug patent expirations by year for TRI-NORINYL 21-DAY

US Patents and Regulatory Information for TRI-NORINYL 21-DAY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Sa TRI-NORINYL 21-DAY ethinyl estradiol; norethindrone TABLET;ORAL-21 018977-001 Apr 13, 1984 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRI-NORINYL 21-DAY

See the table below for patents covering TRI-NORINYL 21-DAY around the world.

Country Patent Number Title Estimated Expiration
New Zealand 201539 PROCESS FOR THE PRODUCTION OF A CONTRACEPTIVE COMPOSITION ⤷  Sign Up
Malaysia 8700596 METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR ⤷  Sign Up
United Kingdom 2104779 METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR ⤷  Sign Up
Hong Kong 26087 METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR ⤷  Sign Up
Australia 8697682 ⤷  Sign Up
Canada 1198057 METHODE DE CONTRACEPTION PAR ADMINISTRATION DE PROGESTOGENE (METHOD OF CONTRACEPTION USING PEAK PROGESTOGEN DOSAGE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TRI-NORINYL 21-DAY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1453521 300814 Netherlands ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521 93156 Luxembourg ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
0771217 CA 2006 00038 Denmark ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
1453521 CA 2016 00016 Denmark ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0398460 C300221 Netherlands ⤷  Sign Up PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076 C01214076/01 Switzerland ⤷  Sign Up PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.